A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 553-558

  Senan, S ^a   Cardenal, F ^b   Vansteenkiste, J ^c   Stigt, J ^d   Akyol, F ^e   de Neve, W ^f   Bakker, J ^g   Dupont, J M ^h   Scagliotti, G V ⁱ   Ricardi, U ^j   van Meerbeeck, J P ^f  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ISALA HOSPITAL   (Netherlands)

^e HACETTEPE UNIVERSITY   (Turkey)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g Medical Affairs and Clinical Operations   (Netherlands)

^h San Luigi Hospital ^*  (France)

ⁱ SAN LUIGI GONZAGA HOSPITAL   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Chemo radiotherapy; Concurrent; Involved field radiotherapy; Sequencing; Stage III lung cancer; Toxicity

Indexed keywords

CISPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG TOXICITY; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME; TUMOR VOLUME; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; LUNG TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DRUG TOXICITY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TAXOIDS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 79952031329     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq388     Document Type: Article

References (31)

1. Robinson LA, Ruckdeschel JC, Wagner H Jr et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3 Suppl): 243S-265S.
2. Vokes EE, Herndon JE 2nd, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-1704.
3. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-5760.
4. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386.
5. Vokes EE, Herndon JE 2nd, Crawford J et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002; 20: 4191-4198.
6. Rowell NP, O'rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004; 18: CD002140.
7. Yuan S, Sun X, Li M et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007; 30: 239-244.
8. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
9. Nyman J, Friesland S, Hallqvist A et al. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer 2009; 65: 62-67.
10. Green MR, West H, Socinski MA et al. Impact of the ASCO 2007 presentation of HOG LUN 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer. J Thorac Oncol 2009; 4: 983-987.
11. Mason KA, Kishi K, Hunter N et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999; 5: 4191-4198.
12. Mason K, Staab A, Hunter N et al. Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 2001; 18: 599-606.
13. Pradier O, Rave-Fränk M, Lehmann J et al. Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki). Int J Cancer 2001; 91: 840-845.
14. Scagliotti GV, Szczesna A, Ramlau R et al. Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer 2006; 94: 1375-1382.
15. Vergnenègre A, Daniel C, Léna H et al. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC). Lung Cancer 2005; 47: 395-404.
16. Senan S, De Ruysscher D, Giraud P et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004; 71: 139-146.
17. van Sörnsen de Koste JR, Senan S, Underberg RW et al. Use of CD-ROM-based tool for analyzing contouring variations in involved-field radiotherapy for Stage III NSCLC. Int J Radiat Oncol Biol Phys 2005; 63: 334-339.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
19. Common Toxicity Criteria classification v3.0 http://ctep.info.nih.gov/reportingctc.html (26 July 2010, date last accessed).
20. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-2456.
21. Fournel P, Vergnenégre A, Robinet G et al. Induction Or Consolidation Chemotherapy With Cisplatin (C) And Paclitaxel (P) Plus Concurrent Chemo-Radiation With Cisplatin And Vinorelbine (V) For Unresectable Non-Small Cell Lung Cancer Patients: Randomized Phase II Trial GFPC-GLOT-IFCT 02-01. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006; 24: 18S (June 20 Suppl), 7048.
22. Garrido Lopez P, Rosell R, Massutí B et al. Predictors of long-term survival in lung cancer patients (p) included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel (D) and carboplatin (Cb) plus induction (I) or consolidation (C) chemotherapy (CT) with docetaxel and gemcitabine (G). J Clin Oncol 2008; 26: (May 20 Suppl; Abstr 7574).
23. Berghmans T, Van Houtte P, Paesmans M et al. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer 2009; 64: 187-193.
24. Belani CP, Choy H, Bonomi P et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23: 5883-5891.
25. Barriger RB, Aseneau JC, Yu M et al. Rates and risk of pneumonitis in non-small cell lung carcinoma (NSCLC) patients treated with concurrent chemoradiation. Int J Rad Oncol Biol Phys 2008; 72: S117-S118.
26. Onishi H, Kuriyama K, Yamaguchi M et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-smallcell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003; 40: 79-84.
27. Sekine I, Nokihara H, Sumi M et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 2006; 1: 810-815.
28. Clamon G, Herndon J, Cooper R et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17: 4-11.
29. Groen HJ, van der Leest AH, Fokkema E et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 2004; 15: 427-432.
30. Gervais R, Ducolone A, LeChevalier T et al. Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT) [vinorelbine (Vr)-cisplatin (P)]: final results of a randomized phase III trial in stage III unresectable non small cell lung (NSCLC) cancer. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005; 23: 16S, Part I of II (June 1 Supplement), 7016.
31. van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 nonsmall-cell lung cancer. J Natl Cancer Inst 2007; 99: 442-450.